Operating Lease, Right-of-Use Asset of Aligos Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Aligos Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Aligos Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $3,089,000, a 38% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Aligos Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $3,089,000 -$1,875,000 -38% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $3,581,000 -$1,813,000 -34% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $4,059,000 -$1,754,000 -30% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $4,648,000 -$1,519,000 -25% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $4,964,000 -$1,595,000 -24% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $5,394,000 -$1,546,000 -22% 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $5,813,000 -$1,499,000 -21% 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $6,167,000 -$1,141,000 -16% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $6,559,000 -$1,139,000 -15% 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $6,940,000 -$1,133,000 -14% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $7,312,000 -$1,129,000 -13% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $7,308,000 -$1,452,000 -17% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $7,698,000 -$1,091,000 -12% 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $8,073,000 +$1,187,000 +17% 30 Sep 2022 10-Q 02 Nov 2022 2022 Q3
Q2 2022 $8,441,000 +$1,643,000 +24% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $8,760,000 +$1,807,000 +26% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $8,789,000 +$1,888,000 +27% 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $6,886,000 -$168,000 -2.4% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $6,798,000 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $6,953,000 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $6,901,000 -$669,000 -8.8% 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $7,054,000 30 Sep 2020 10-Q 25 Nov 2020 2020 Q3
Q4 2019 $7,570,000 31 Dec 2019 10-K 23 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.